X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pfizer: Coming back to health - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Sep 21, 2004

    Pfizer: Coming back to health

    Pfizer India is one of the leading MNC pharma companies operating in India. It is a 40% subsidiary of the world's largest pharma company Pfizer Inc, which had sales of US$ 40 bn in 2003. It is a leading company in the Indian markets with key brands such as Corex (a cough syrup) and Becosules (a B-complex supplement), the two being brands with a revenue of over Rs 1 bn each. Most of the company's products are OTC (over the counter) products with strong brand equity.

    The global merger of Pfizer with Parke-Davis and Pharmacia has led to a consolidation of these companies in India as well. These two mergers have significantly improved the therapeutic coverage of the company. Although the company derives a majority of its revenues from the pharma business, it also has a presence in animal health and clinical development operations. During the year ended November 2003, while the pharmaceutical business contributed 86% to the total revenues, the animal health segment contributed about 10% to the total revenues and clinical development operations contributed 4% to the revenues.

    In the Clinical development segment, Pfizer recorded a 20% growth in FY04. The company carries out clinical trials on behalf of the parent company. Although, this business proposition offers lot of scope for revenue growth to the company going forward, the revenues from this segment will depend upon the ability of the company to obtain further contracts from its' parent.

    Now, turning to the company's performance in the recent quarters, one observes that they have not been very encouraging for the company. Both sales as well as profits have declined. The basic reason for the fall in sales is the general slow down in the domestic pharma market. Since the company is dependent on a very few products for its revenues a slowdown is likely to impact Pfizer the most. Also in the second quarter ending May 04 the company faced problems with the quality of one of its leading brands Gelusil (Rs 300 m in sales).

    Also, the work force rationalization exercise has put pressure on the company's profitability in FY04. Pfizer had written off Rs 167 m during the FY04 on account of VRS (Voluntary Retirement Scheme). The company's work force rationalization exercise has been continuing from FY02 and the impact can be gauged from the fact that the sales of the company has almost doubled in last four years (from FY00 to FY04) but the total number of employees has grown by only 40%.

    Over the years Pfizer has time and again delivered good results in terms of sales and profits. The chart below shows the revenue growth as well as the trend of operating margin and net profit margin of the company in last five years. The number after 2003 include the merger with Parke Davis.

    Going forward, as the management has indicated the company will move from being a pure OTC player to the prescription drugs market and it may launch several drugs in that category. However, with the new patent regime, which is likely to be implemented by Jan 2005, the company is likely to gain significantly as the parent has a large pipeline of patented drugs to offer to the Indian markets. Also with the completion of the employee rationalisation process we are likely to witness an improvement in margins, a glimpse of which was seen in the quarter ending May 2004.

    The stock is trading at Rs 503, a P/E multiple of 33x, based on its annualized 1HFY05 earnings Though valuations look stretched, one must remember that Pfizer is in a phase where growth in the profits will be faster than its sales growth since the full benefits of the restructuring is yet to come. Apart from this the new patent regime will bring in benefits for the company in the form of new product launches as we believe that the company is likely to aggressively explore this market opportunity, which is likely to contribute to a higher topline growth in the future.

     

     

    Equitymaster requests your view! Post a comment on "Pfizer: Coming back to health". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    PFIZER SHARE PRICE


    Aug 21, 2017 12:32 PM

    TRACK PFIZER

    PFIZER 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE PFIZER WITH

    MARKET STATS